Logo
LongevHA – NAD+ Skin Booster (1×2.5ml)

LongevHA – NAD+ Skin Booster (1×2.5ml)

LongevHA

Skin boosters
  • Marketed as a professional injectable skin booster for aesthetic use; not listed as a licensed medicinal product on the MHRA medicines database.
  • At least one UK distributor explicitly notes that LongevHA is not CE Marked as a medical device; practitioners should treat it as a non CE Marked aesthetic product and follow local regulatory guidance.
  • Supplied through registered aesthetic pharmacies and wholesalers that operate under applicable UK regulatory frameworks for prescription Only and aesthetic products.
  • For use only by appropriately trained and licensed aesthetic practitioners in line with local clinical governance and consent requirements.
Injectable biorevitalising skin booster

Description

LongevHA – NAD+ Skin Booster (1×2.5ml) is a next-generation biorevitalising injectable skin booster that combines highly concentrated dual-weight hyaluronic acid (80 mg per 2.5 ml) with NAD⁺, resveratrol, mannitol and peptides. It targets cellular ageing pathways by activating SIRT1 (a key longevity-associated gene), delivering deep hydration, collagen stimulation, antioxidant protection and support for skin barrier integrity. Designed for professional use on the face, neck, décolleté and hands, it helps improve elasticity, smooth fine lines, refine texture and promote a more radiant, youthful complexion.

Bnefits

  • Intensive hydration and lifting – high molecular weight hyaluronic acid (40 mg) provides robust surface hydration, improving skin plumpness and elasticity.
  • Collagen boost and inflammation modulation – low molecular weight hyaluronic acid (40 mg) supports collagen type III production, growth factors and inflammatory balance for firmer, more resilient skin.
  • Potent antioxidant support – resveratrol helps neutralise oxidative stress, soothe the skin and works synergistically with NAD⁺ to encourage cellular renewal.
  • Longevity and barrier support – NAD⁺ helps regulate gene expression, supports cellular energy metabolism and activates sirtuins (including SIRT1), key regulators of youthful-looking skin.
  • Free-radical protection and HA preservation – mannitol acts as an antioxidant, helps reduce post-injection inflammation and protects hyaluronic acid from breakdown to prolong its effect.
  • Biorevitalising action – combination of HA, NAD⁺, resveratrol, mannitol and peptides provides both immediate hydration and longer-term improvements in texture, tone and fine lines.

Indications

  • Clinical biorevitalisation of photo-aged and chronologically aged skin.
  • Fine lines and superficial wrinkles on the face, neck, décolleté and hands.
  • Loss of elasticity, firmness and skin turgor.
  • Dull, dehydrated or tired-looking skin requiring deep hydration and glow.
  • Supportive treatment to improve overall skin quality and texture.

Composition

  • Hyaluronic acid 3.2% (80 mg per 2.5 ml) – dual molecular weight (40 mg high molecular weight, 40 mg low molecular weight).
  • Mannitol – antioxidant polyol that helps limit HA degradation and reduce post-injection inflammation.
  • NAD⁺ (nicotinamide adenine dinucleotide) – cofactor involved in cellular energy metabolism and SIRT1 activation.
  • Resveratrol – polyphenolic antioxidant that helps counter oxidative stress and supports cellular longevity pathways.
  • Peptides – bioactive peptides to support dermal matrix and regenerative processes.
  • Buffering and carrier components suitable for injectable HA skin boosters (exact excipient list not fully disclosed publicly).

Formulation

  • Biorevitalising injectable gel based on non-permanently cross-linked hyaluronic acid with dual molecular weight profile (HMW + LMW).
  • Total HA content: 3.2% w/v (80 mg in 2.5 ml).
  • Contains NAD⁺, resveratrol, mannitol and peptides for combined hydration, antioxidant and longevity-targeted effects.
  • Viscosity: medium to high, designed to provide structural support while remaining suitable for dermal or subdermal injection.
  • Sterile, apyrogenic formulation for single-patient use by trained aesthetic professionals.

Packaging

  • 1 pre-filled sterile syringe × 2.5 ml LongevHA skin booster per box.
  • Supplied with standard luer-lock connection compatible with aesthetic injection needles and cannulas (needles not included).
  • Single-use syringe intended for one patient only; remainder must be discarded after use.
  • Outer carton with product identification, batch number and expiry date.

Usage

  • For professional use only; to be administered by licensed healthcare professionals or trained aesthetic practitioners in accordance with local regulations.
  • Typical treatment areas include face, neck, décolleté and hands, targeting regions with fine lines, laxity or visible dehydration.
  • Administer via intradermal or superficial to mid-dermal injections (e.g. micro-papular, serial puncture or mesotherapy-style techniques) or using a suitable cannula for linear/threading techniques, according to practitioner training and patient needs.
  • Apply using aseptic technique on cleaned and disinfected skin; appropriate pre-treatment skin preparation and post-treatment care should be followed.
  • Treatment protocols vary; commonly an initial course of sessions spaced several weeks apart is followed by periodic maintenance sessions, tailored to the individual’s skin status and practitioner judgement.
  • Do not inject into blood vessels, areas of active infection or inflammation, or into previously implanted permanent fillers.
  • Discard any unused product after the session; do not resterilise or reuse the syringe.

Contraindications

  • History of hypersensitivity or allergy to hyaluronic acid, resveratrol, mannitol, peptides, NAD⁺ or any component of the formulation.
  • Presence of active skin infection, inflammation, herpetic lesions, acne flares or dermatitis at the proposed injection site.
  • Known severe allergy or anaphylactic history to injectable aesthetic products.
  • Autoimmune diseases or immunocompromised status, unless the treating physician considers use appropriate after risk–benefit assessment.
  • Pregnancy and breastfeeding, due to lack of established safety data in these populations.
  • History of hypertrophic scarring or keloid formation in the planned treatment area.
  • Concurrent use of anticoagulants or antiplatelet medications may increase bruising risk; practitioner should evaluate individual bleeding risk before treatment.

Adverse Effects

  • Common, usually transient effects at injection sites such as redness (erythema), swelling, tenderness, itching, mild pain, pinpoint bleeding and bruising.
  • Transient small papules or nodules at injection sites, generally resolving as the product integrates into the tissue.
  • Localised oedema or mild inflammatory reactions, typically self-limiting.
  • Less common reactions may include prolonged swelling, induration, unevenness or palpable lumps requiring clinical assessment and possible intervention.
  • Rare but more serious complications, as with other injectable HA products, may include infection, granuloma formation, hypersensitivity reactions or vascular compromise; prompt recognition and management by an experienced practitioner is essential.
  • Post-injection pigmentation changes in predisposed individuals, particularly in darker skin phototypes, if inflammation or bruising is marked.

Storage Conditions

  • Store in a cool, dry place at a controlled room or refrigerated temperature typically between 2°C and 25°C, according to pack labelling.
  • Do not freeze; freezing may damage the hyaluronic acid gel structure.
  • Protect from direct sunlight and excessive heat.
  • Keep in the original blister and carton until use to maintain sterility and protect from physical damage.
  • Do not use after the expiry date or if the syringe, blister or packaging appears damaged or previously opened.
  • Keep out of the sight and reach of children.

Duration

Clinically visible improvements in hydration and radiance are often observed shortly after treatment, with structural and collagen-related benefits developing over subsequent weeks. Many distributors describe results lasting several months, with some suggesting longevity up to approximately 12\u201318 months depending on individual factors, treatment protocol and lifestyle. Ongoing maintenance sessions are typically recommended.

Onset

Hydration and plumping effects can appear almost immediately after treatment, with progressive improvements in texture, elasticity and fine lines generally developing over the following 2\u20136 weeks as dermal remodelling and collagen stimulation occur.

Browse more Skin boosters

Top Treatments

Top Cities in the UK